Trial Profile
A Single Center Phase Ib Study of Carfilzomib, Bendamustine, and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.
- 10 Jun 2020 Planned primary completion date changed from 30 Apr 2020 to 30 Apr 2021.
- 12 Sep 2018 Planned End Date changed from 1 Apr 2021 to 30 Apr 2021.